Telomerase as a therapeutic target

• Autorzy: Huminiecki L.
• Języki publikacji: EN

Abstrakty

EN

Ribonucleoprotein telomerase is an enzyme that elongates telomeric DNA. In cells without detectable telomerase activity telomeres shorten with every cell generation and reaching critical length is a signal for cell death. Normal human somatic cells express undetectable, or low (bone marrow and peripheral leukocytes), telomerase activity. Reactivation of telomerase (immortalization) is probably necessary during development of a fully malignant cancer. Consequently, telomerase was proposed to be a therapeutic target for the cancer therapy. Potential results (including side-effects) of telomerase inhibition are being considered. After all, telomerase inhibition can be useful not only in the therapy, but also in cancer biology research, elucidating ageing and immortalization phenomena.

Słowa kluczowe

EN

gene therapy; anticancer effect; man; carcinogenesis; normal somatic cell; telomerase activity; cancer therapy

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1996
• Tom: 43
• Numer: 3
• Opis fizyczny: p.531-538,fig.

Twórcy

autor

Huminiecki L.

• Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland

Bibliografia

• 1. Blackburn, E.I I. (1991) Structure and function of telomeres. Nature (London) 350,569-573.
• 2. Blackburn, E.H. (1992) Telomerases. Annu. Rev. Biochem. 61,113-129.
• 3. Harley, C.B., Vaziri, H., Counter, C.M. & AI1- sopp, R.C. (1992) The telomere hypothesis of cellular ageing. Exp. Gerontol. 27,375-382.
• 4. Allsopp, R.C., Vaziri, 11, Patterson, C., Gold­stein, S., Younglai, E.V., Futhcr, A.B., Grcide, C.W. & Harley, C.B. (1992) Telomere lenght- ening predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 89, 10114-10118.
• 5. Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L., Coviello, G.M.. Wright, W.E., Weinrich, S.L. & Shay, J.W. (1994) Specific associations of human telo­merase activity with immortal cells and cancer. Science 266,2011-2015.
• 6. Giraroli, A.J., Jensen, F.C. & Koprowski, H. (1969) SV40-induced transformation of human diploid cells: Crisis and recovery. Int. J. Natl. Cancer Inst. 42,867-870.
• 7. Counter, C.M., Botelho, F., Harley, C.B. & Bacch- ctti, S. (1994) Stabilization of short telomeres and telomerase activity accompany immorta­lization of Epstein-Barr virus transformed human B lymphocytes. /. Virol. 68,3410-3414.
• 8. Steel, M. (1995) Telomerase that shapes our ends. Lancet 345,935-936.
• 9. Counter, M.C., Gupta. J., Harley, C.B., Leber, B. & Bacchetti, S. (1995) Telomerase activity in nor­mal leukocytes and in hematologic malig­nancies. Blood 85,2315-2320.
• 10. Schwartz, H.S., Juliao, S.F. & Sciadini, M.F. (1995) Telomerase activity and oncogenesis in giant cell tumor of bone. Cancer 75,1094-1098.
• 11. Blasco, M.A., Funk, W., Villeponteau, B. & Gre- ider, C.W. (1995) Functional characterization and developmental regulation of mouse telomerase RNA. Science 268,1267-1270.
• 12. Huminiecki, L. (1995) Gene therapy — vectors and strategies. Adv. Biochem. 4,220-230.
• 13. Fujiwara, T., Grim, E.A., Mukhopadhyay, T., Cai, D.W., Owen-Schaub, L.B. & Roth,' J.A. (1993) A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53,4129-4133.
• 14. Zhang, Y., Mukhopartyay,T., Donehower, LA., Georges, R.N. & Roth, J.A. (1993) Retroviral vector-mediated transduction of K-ras anti- sense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum. Gene. Ther. 4,451-460.
• 15. Ratajczak, M.Z., Kant,J.A. & Luger,S.M., 1 lijiya, N., Zhang, J., Zon, G. & Gewirtz, M. (1992) In vivo treatment of human leukaemia in a scid mouse model with c-myb antisease oligodeoxy- nucleotides. Proc. Natl. Acad. Sci. U.S.A. 89, 11823-11827.
• 16. Skorski, T., Nieborowska-Skorska, M. & Nicola- ides, N.C. (1994) Suppression of Philadelphia 1 leukaemia cell growth in mice by BCR-ABL antisense oligonucletide. Proc. Natl. Acad. Sci. U.S.A. 91,4504-4508.
• 17. Lange, W., Cantin, E.M., Finke, J. & Dolken, G. (1993) In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. leukemia 11,1786-1794.
• 18. Counter, C.M. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO /. 11,1921-1929.
• 19. Shay, J.W., Wright, W.E. & Brasiskite, D. (1993) E6 of human papillomavirus type 16 can overcome the Ml stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 8,1407-1413.
• 20. Vaziri, H., Dragowska, W. & Allsopp, R.C. (1994) Evidence for a mitotic clock in human hemato­poietic stem cells, loss of telomeric DNA with age. Proc. Natl. Acad. Sci. U.S.A. 91,9857-9860.
• 21. Feng, J., Funk, W.D., Wang, S.S., Weinrich, S.L., Avilion, A.A., Chiv, CP., Adams, R.R., Chang, E., Allsopp, R.C. & Yu, J. (1995) The RNA component of human telomerase. Science 269, 1236-1240.
• 22. Allen, T.M. (1994) l-ong-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 15,215-220.
• 23. Kashani-Sabet, M. & Scanlon, J.K. (1995) Application of ribozymes to cancer therapy. Cancer Gene Ther. 2,213-223.
• 24. Mercola, D. & Cohen, J.S. (1995) Antisense approaches to cancer therapy- Cancer Gene Ther. 2,47-59.
• 25. Gotten, M., Schaffner, G. & Birnstiel, M.L. (1989) Ribozyme, antisense RNA, antisense DNA inhibition of U7 small nuclear ribonucleo- protein-mediated histone pre-mRNA process­ing in vitro. Mol. Cell. Biol. 9,4479-4487.
• 26. Bridges, S.H. & Sarver, N. (1995) Gene therapy and immune restoration for HIV disease. lancet 345, 427-432.
• 27. Lever, A.M.L. (1995) Gene therapy for HIV infection. Brit. Med. Bull. 51,149-166.
• 28. Kipling, D. (1995) Telomerase: Immortalising enzyme or oncogene. Nature Genetics 9,104-106.
• 29. Prowse, K.R. & Greider, C.W. (1995) Develop­mental and tissue-specific regulation of mouse telomerase and telomere length. Proc. Natl. Acad. Sci. U.S.A. 92,4818-4822.
• 30. Morin, G.B. (1995) Is telomerase a universal cancer target? /. Natl. Cane. Inst. 87,859-862.
• 31. Bednarek, A., Budunova, I., Slaga, T.J. & Aldaz, C.M. (1995) Increased telomerase activity inmouse skin premalignant progression. Cancer Res. 55,4566-4569.
• 32. Bhattacharya, A. & Blackburn, E.H. (1995) Architecture of telomerase RNA. FMBO }. 13, 5721-5731.
• 33. McCormick-G ra ha m, M. & Romero, O.P. (1995) Ciliate telomerase RNA structural features. Nucleic Acids Res. 23,1091-1097.
• 34. Greider, C.W. (1990) Telomeres, telomerase and senescence. Bio-Essays 12, 363-369.